TY - JOUR
T1 - Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer
T2 - A systematic review with meta-analysis
AU - Luchini, Claudio
AU - Wood, Laura D.
AU - Cheng, Liang
AU - Nottegar, Alessia
AU - Stubbs, Brendon
AU - Solmi, Marco
AU - Capelli, Paola
AU - Pea, Antonio
AU - Sergi, Giuseppe
AU - Manzato, Enzo
AU - Fassan, Matteo
AU - Bagante, Fabio
AU - Bollschweiler, Elfriede
AU - Giacopuzzi, Simone
AU - Kaneko, Takuma
AU - De Manzoni, Giovanni
AU - Barbareschi, Mattia
AU - Scarpa, Aldo
AU - Veronese, Nicola
N1 - Publisher Copyright:
© Published by the BMJ Publishing Group Limited.
PY - 2016/11
Y1 - 2016/11
N2 - The extranodal extension (ENE) of nodal metastasis is the extension of neoplastic cells through the nodal capsule into the perinodal adipose tissue. This histological feature has recently been indicated as an important prognostic factor in different types of malignancies; in this manuscript, we aim at defining its role in the prognosis of oesophageal cancer with the tool of meta-analysis. Two independent authors searched SCOPUS and PubMed until 31 August 2015 without language restrictions. The studies with available data about prognostic parameters in subjects with oesophageal cancer, comparing patients with the presence of ENE (ENE+) versus only intranodal extension (ENE-), were considered as eligible. Data were summarised using risk ratios (RRs) for number of deaths/recurrences and HRs together with 95% CIs for time-dependent risk related to ENE+, adjusted for potential confounders. Fourteen studies were selected; they followed-up 1437 patients with oesophageal cancer for a median follow-up of 39.4months. The presence of ENE was associated with a significantly increased risk of all-cause mortality (RR=1.33; 95% CI 1.18 to 1.50, p<0.0001, I 2 =49%; HR=2.72, 95% CI 2.03 to 3.64, p<0.0001, I 2 =0%), cancer-specific mortality (RR=1.35; 95% CI 1.14 to 1.59, p=0.001, I 2 =57%; HR=1.97, 95% CI 1.41 to 2.75, p<0.0001, I 2 =41%) and of risk of recurrence (RR=1.50, 95% CI 1.20 to 1.88, p<0.0001, I 2 =9%; HR=2.27, 95% CI 1.72 to 2.90, p<0.0001, I 2 =0%). On the basis of these results, in oesophageal cancer, ENE should be considered from the gross sampling to the pathology report, and in future oncological staging system.
AB - The extranodal extension (ENE) of nodal metastasis is the extension of neoplastic cells through the nodal capsule into the perinodal adipose tissue. This histological feature has recently been indicated as an important prognostic factor in different types of malignancies; in this manuscript, we aim at defining its role in the prognosis of oesophageal cancer with the tool of meta-analysis. Two independent authors searched SCOPUS and PubMed until 31 August 2015 without language restrictions. The studies with available data about prognostic parameters in subjects with oesophageal cancer, comparing patients with the presence of ENE (ENE+) versus only intranodal extension (ENE-), were considered as eligible. Data were summarised using risk ratios (RRs) for number of deaths/recurrences and HRs together with 95% CIs for time-dependent risk related to ENE+, adjusted for potential confounders. Fourteen studies were selected; they followed-up 1437 patients with oesophageal cancer for a median follow-up of 39.4months. The presence of ENE was associated with a significantly increased risk of all-cause mortality (RR=1.33; 95% CI 1.18 to 1.50, p<0.0001, I 2 =49%; HR=2.72, 95% CI 2.03 to 3.64, p<0.0001, I 2 =0%), cancer-specific mortality (RR=1.35; 95% CI 1.14 to 1.59, p=0.001, I 2 =57%; HR=1.97, 95% CI 1.41 to 2.75, p<0.0001, I 2 =41%) and of risk of recurrence (RR=1.50, 95% CI 1.20 to 1.88, p<0.0001, I 2 =9%; HR=2.27, 95% CI 1.72 to 2.90, p<0.0001, I 2 =0%). On the basis of these results, in oesophageal cancer, ENE should be considered from the gross sampling to the pathology report, and in future oncological staging system.
KW - CANCER
KW - METASTASIS
KW - OESOPHAGUS
UR - http://www.scopus.com/inward/record.url?scp=84978828807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978828807&partnerID=8YFLogxK
U2 - 10.1136/jclinpath-2016-203830
DO - 10.1136/jclinpath-2016-203830
M3 - Review article
C2 - 27387986
AN - SCOPUS:84978828807
SN - 0021-9746
VL - 69
SP - 956
EP - 961
JO - Molecular pathology : MP
JF - Molecular pathology : MP
IS - 11
ER -